1
|
Wang Y, Fang L, Wang Y, Xiong Z. Current Trends of Raman Spectroscopy in Clinic Settings: Opportunities and Challenges. ADVANCED SCIENCE (WEINHEIM, BADEN-WURTTEMBERG, GERMANY) 2024; 11:e2300668. [PMID: 38072672 PMCID: PMC10870035 DOI: 10.1002/advs.202300668] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/30/2023] [Revised: 09/08/2023] [Indexed: 02/17/2024]
Abstract
Early clinical diagnosis, effective intraoperative guidance, and an accurate prognosis can lead to timely and effective medical treatment. The current conventional clinical methods have several limitations. Therefore, there is a need to develop faster and more reliable clinical detection, treatment, and monitoring methods to enhance their clinical applications. Raman spectroscopy is noninvasive and provides highly specific information about the molecular structure and biochemical composition of analytes in a rapid and accurate manner. It has a wide range of applications in biomedicine, materials, and clinical settings. This review primarily focuses on the application of Raman spectroscopy in clinical medicine. The advantages and limitations of Raman spectroscopy over traditional clinical methods are discussed. In addition, the advantages of combining Raman spectroscopy with machine learning, nanoparticles, and probes are demonstrated, thereby extending its applicability to different clinical phases. Examples of the clinical applications of Raman spectroscopy over the last 3 years are also integrated. Finally, various prospective approaches based on Raman spectroscopy in clinical studies are surveyed, and current challenges are discussed.
Collapse
Affiliation(s)
- Yumei Wang
- Department of NephrologyUnion HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan430022China
| | - Liuru Fang
- Hubei Province Key Laboratory of Systems Science in Metallurgical ProcessWuhan University of Science and TechnologyWuhan430081China
| | - Yuhua Wang
- Hubei Province Key Laboratory of Systems Science in Metallurgical ProcessWuhan University of Science and TechnologyWuhan430081China
| | - Zuzhao Xiong
- Hubei Province Key Laboratory of Systems Science in Metallurgical ProcessWuhan University of Science and TechnologyWuhan430081China
| |
Collapse
|
2
|
Wang S, Huang X, Zhang G, Chen Z, Guan H, Zhou W. Tumor suppressor miR-361-3p inhibits prostate cancer progression through Gli1 and AKT/mTOR signaling pathway. Cell Signal 2024; 114:110998. [PMID: 38048859 DOI: 10.1016/j.cellsig.2023.110998] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Revised: 11/20/2023] [Accepted: 11/30/2023] [Indexed: 12/06/2023]
Abstract
BACKGROUND The primary challenge in prostate cancer (PCa) is tumor metastasis, which seriously affects the survival time of patients. Growing evidence suggests that microRNAs play a crucial regulatory role in various malignancies and that the tumor suppressor miR-361-3p is responsible for regulating migration, proliferation, and invasion in different cancer types. However, the underlying regulatory mechanism of miR-361-3p in PCa remains unknown. METHODS The expression of miR-361-3p in PCa cells was analyzed using quantitative real time-polymerase chain reaction. The clinical utility of miR-361-3p in PCa was evaluated using in vitro assays. The mechanism of action of miR-361-3p was investigated using western blotting, luciferase reporter assays, immunofluorescence, and rescue studies. RESULTS The function, invasiveness, migration, and proliferation of PCa cells, as well as epithelial-mesenchymal transition (EMT), were aided by the downregulation of miR-361-3p, whereas its overexpression exerted the opposite effect. Repression of glioma-associated oncogene homolog 1 (Gli1) expression by miR-361-3p led to activation of the protein kinase B/mammalian target of rapamycin (AKT/mTOR) signaling pathway, triggering EMT and promoting PCa metastasis. CONCLUSIONS Downregulation of miR-361-3p along the Gli1 axis promoted tumor malignancy. Collectively, the results of this study imply that miR-361-3p has the potential to be both a biomarker and therapeutic target in PCa.
Collapse
Affiliation(s)
- Shaocheng Wang
- Chongming Hospital Affiliated to Shanghai University of Medicine and Health Sciences, Shanghai 201318, China; Department of Urology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui Province 233099, China
| | - Xiaoyu Huang
- Department of Urology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui Province 233099, China
| | - Guangyu Zhang
- Department of Urology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui Province 233099, China
| | - Zhijun Chen
- Department of Urology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui Province 233099, China
| | - Han Guan
- Department of Urology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui Province 233099, China.
| | - Wensheng Zhou
- Department of Urology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui Province 233099, China.
| |
Collapse
|
3
|
Jiang F, Zhai G, Liu J, Wang R, Yang Y, Murugesan H, Yu X, Du X, He J, Feng Z, Pan SL, Chen G, Li S, Huang Z. High expression of centromere protein A and its molecular mechanism and clinical significance in prostate cancer: A study based on data mining and immunohistochemistry. IET Syst Biol 2023; 17:245-258. [PMID: 37488766 PMCID: PMC10579994 DOI: 10.1049/syb2.12073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2022] [Revised: 05/30/2023] [Accepted: 07/09/2023] [Indexed: 07/26/2023] Open
Abstract
The progression of prostate cancer (PCa) leads to poor prognosis. However, the molecular mechanism of PCa is still not completely clear. This study aimed to elucidate the important role of centromere protein A (CENPA) in PCa. Large numbers of bulk RNA sequencing (RNA-seq) data and in-house immunohistochemistry data were used in analysing the expression level of CENPA in PCa and metastatic PCa (MPCa). Single-cell RNA-seq data was used to explore the expression status of CENPA in different prostate subpopulations. Enrichment analysis was employed to detect the function of CENPA in PCa. Clinicopathological parameters analysis was utilised in analysing the clinical value of CENPA. The results showed that CENPA was upregulated in PCa (standardised mean difference [SMD] = 0.83, p = 0.001) and MPCa (SMD = 0.61, p = 0.029). CENPA was overexpressed in prostate cancer stem cells (CSCs) with androgen receptor (AR) negative compared to epithelial cells with AR positive. CENPA may influence the development of PCa through affecting cell cycle. Patients with nodal metastasis had higher expression level of CENPA. And patients with high CENPA expression had poor disease-free survival. Taken together, Overexpression of CENPA may influence the development of PCa by regulating cell cycle and promoting metastasis.
Collapse
Affiliation(s)
- Fang‐Cheng Jiang
- Department of PathologyThe First Affiliated Hospital of Guangxi Medical UniversityNanningChina
| | - Gao‐Qiang Zhai
- Department of UrologyThe First Affiliated Hospital of Guangxi Medical UniversityNanningChina
| | - Jia‐Lin Liu
- Department of UrologyThe First Affiliated Hospital of Guangxi Medical UniversityNanningChina
| | - Rui‐Gong Wang
- Department of UrologyThe First Affiliated Hospital of Guangxi Medical UniversityNanningChina
| | - Yuan‐Ping Yang
- Department of PathologyThe First Affiliated Hospital of Guangxi Medical UniversityNanningChina
| | - Harivignesh Murugesan
- Department of PathologyThe First Affiliated Hospital of Guangxi Medical UniversityNanningChina
| | - Xiao‐Xiang Yu
- Department of UrologyThe 923rd Hospital of Chinese People's Liberation Army Joint Logistics Support ForceNanningChina
| | - Xiu‐Fang Du
- Department of PathologyThe First Affiliated Hospital of Guangxi Medical UniversityNanningChina
| | - Juan He
- Department of PathologyThe First Affiliated Hospital of Guangxi Medical UniversityNanningChina
| | - Zhen‐Bo Feng
- Department of PathologyThe First Affiliated Hospital of Guangxi Medical UniversityNanningChina
| | - Shang Ling Pan
- Department of PathophysiologySchool of Pre‐clinical MedicineGuangxi Medical UniversityNanningGuangxiChina
| | - Gang Chen
- Department of PathologyThe First Affiliated Hospital of Guangxi Medical UniversityNanningChina
| | - Sheng‐Hua Li
- Department of UrologyThe First Affiliated Hospital of Guangxi Medical UniversityNanningChina
| | - Zhi‐Guang Huang
- Department of PathologyThe First Affiliated Hospital of Guangxi Medical UniversityNanningChina
| |
Collapse
|
4
|
Chowdhury SG, Ray R, Karmakar P. Exosomal miRNAs-a diagnostic biomarker acting as a guiding light in the diagnosis of prostate cancer. Funct Integr Genomics 2022; 23:23. [PMID: 36574059 DOI: 10.1007/s10142-022-00951-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2022] [Revised: 12/21/2022] [Accepted: 12/22/2022] [Indexed: 12/28/2022]
Abstract
Prostate cancer, one of the major causes of mortality globally is regarded as the second leading cause of mortality among men. It is known to affect the stromal cells surrounding it. Through the use of exosomes, the affected stromal cells can promote the growth and spread of the cancer. Exosomes are known to play a role not only in the development and progression of cancer but also contribute to the drug-resistance character of cancer cells. Recently, the discovery of the small non-coding RNAs or miRNA has attracted attention of cancer researchers as they can regulate the expression of different genes. Therefore, exosomal miRNA can be used as a novel and reliable biomarker for the diagnosis and treatment of prostate cancer. In addition, exosomal miRNAs can also be used as a potential treatment for prostate cancer. The goal of this review is to provide a comprehensive analysis of the current knowledge about the role of exosomal miRNAs in the treatment of patients with prostate cancer and their potential role in monitoring the disease.
Collapse
Affiliation(s)
| | - Rachayeeta Ray
- Department of Life Science and Biotechnology, Jadavpur University, Kolkata, 700032, India
| | - Parimal Karmakar
- Department of Life Science and Biotechnology, Jadavpur University, Kolkata, 700032, India.
| |
Collapse
|
5
|
Singh A, Khan DUZ, Singh P, Singh AK, Agarwal P. Prognostic utility of microRNA-145 and CD 133 in oral squamous cell carcinoma: A pilot study from Northern India. J Oral Biol Craniofac Res 2022; 13:92-95. [DOI: 10.1016/j.jobcr.2022.11.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2022] [Accepted: 11/30/2022] [Indexed: 12/03/2022] Open
|
6
|
Huang SW, Luo JY, Qin LT, Huang SN, Huang ZG, Dang YW, He J, Zeng JH, Wei ZX, Lu W, Chen G. Up-regulation of ITGAV and the underlying mechanisms in nasopharyngeal carcinoma. ELECTRON J BIOTECHN 2022. [DOI: 10.1016/j.ejbt.2022.09.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
7
|
Chen Z, Xiao Z, Zeng S, Yan Z. The potential value of microRNA-145 for predicting prognosis in patients with ovarian cancer: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021; 100:e26922. [PMID: 34397934 PMCID: PMC8360411 DOI: 10.1097/md.0000000000026922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/21/2021] [Accepted: 07/27/2021] [Indexed: 01/04/2023] Open
Abstract
BACKGROUND As an anticancer gene, microRNA-145 (miRNA-145) inhibits the growth, migration, and invasion of cancer cells, and inhibits tumorigenesis by targeting various genes that are abnormally expressed in tumors. However, whether miRNA-145 can be applied as a biomarker for potential prognosis of ovarian cancer still remains controversial. Therefore, this study further explored the prognostic value and mechanism of miRNA-145 in ovarian cancer through meta-analysis and bioinformatics analysis. METHODS Eligible studies were identified by searching the China National Knowledge Infrastructure, Chinese Biomedical literature Database, Chinese Scientific and Journal Database, Wan Fang database, PubMed, EMBASE, and Web of Science up to July 2021. Pooled hazard ratios with 95% confidence intervals for patient survival were calculated to investigate the effects of miRNA-145 on the prognosis of ovarian cancer. Survival curves of differential expression of miRNA-145 were analyzed by Oncomir. The target genes of miRNA-145 were predicted by miRTARbase and Diana-Tarbase V7.0 database. Enrichr database was applied to analyze the target genes by gene ontology and Kyoto Encyclopedia of Genes and Genomes pathways. Protein-protein interaction network of target genes was constructed from STRING database. Cytoscape software was used to screen the hub genes to meet the requirements. The Gene Expression Profiling Interactive Analysis database was applied to analyze the survival outcomes of hub genes. RESULTS The results of this meta-analysis would be submitted to peer-reviewed journals for publication. CONCLUSION This study provides high-quality evidence to support the relationship between miRNA-145 expression and ovarian cancer prognosis. Through bioinformatics analysis, we further explored the mechanism of miRNA-145 in ovarian cancer and related pathways.
Collapse
|
8
|
Martínez-González LJ, Sánchez-Conde V, González-Cabezuelo JM, Antunez-Rodríguez A, Andrés-León E, Robles-Fernandez I, Lorente JA, Vázquez-Alonso F, Alvarez-Cubero MJ. Identification of MicroRNAs as Viable Aggressiveness Biomarkers for Prostate Cancer. Biomedicines 2021; 9:biomedicines9060646. [PMID: 34198846 PMCID: PMC8227559 DOI: 10.3390/biomedicines9060646] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2021] [Revised: 05/22/2021] [Accepted: 06/01/2021] [Indexed: 12/13/2022] Open
Abstract
MiRNAs play a relevant role in PC (prostate cancer) by the regulation in the expression of several pathways’ AR (androgen receptor), cellular cycle, apoptosis, MET (mesenchymal epithelium transition), or metastasis. Here, we report the role of several miRNAs’ expression patterns, such as miR-93-5p, miR-23c, miR-210-3p, miR-221-3p, miR-592, miR-141, miR-375, and miR-130b, with relevance in processes like cell proliferation and MET. Using Trizol® extraction protocol and TaqMan™ specific probes for amplification, we performed miRNAs’ analysis of 159 PC fresh tissues and 60 plasmas from peripheral blood samples. We had clinical data from all samples including PSA, Gleason, TNM, and D’Amico risk. Moreover, a bioinformatic analysis in TCGA (The Cancer Genome Atlas) was included to analyze the effect of the most relevant miRNAs according to aggressiveness in an extensive cohort (n = 531). We found that miR-210-3p, miR-23c, miR-592, and miR-93-5p are the most suitable biomarkers for PC aggressiveness and diagnosis, respectively. In fact, according with our results, miR-93-5p seems the most promising non-invasive biomarker for PC. To sum up, miR-210-3p, miR-23c, miR-592, and miR-93-5p miRNAs are suggested to be potential biomarkers for PC risk stratification that could be included in non-invasive strategies such as liquid biopsy in precision medicine for PC management.
Collapse
Affiliation(s)
- Luis Javier Martínez-González
- GENYO. Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, Genomics Unit, PTS Granada-Avenida de la Ilustración, 114-18016 Granada, Spain;
- Correspondence: author: (L.J.M.-G.); (M.J.A.-C.); Tel.: +34-958-715-500 (ext. 108) (L.J.M.-G.); +34-958-248-945 (M.J.A.-C.); Fax: +34-958-637-071 (L.J.M.-G.)
| | - Victor Sánchez-Conde
- Urology Department, Hospital Virgen de las Nieves, 18014 Granada, Spain; (V.S.-C.); (F.V.-A.)
| | | | - Alba Antunez-Rodríguez
- GENYO. Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, Genomics Unit, PTS Granada-Avenida de la Ilustración, 114-18016 Granada, Spain;
| | - Eduardo Andrés-León
- Bioinformatics Unit, Institute of Parasitology and Biomedicine “López-Neyra” (IPBLN), Spanish National Research Council (CSIC), 18016 Granada, Spain;
| | - Inmaculada Robles-Fernandez
- GENYO. Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, Liquid Biopsy and Cancer Interception Group, PTS Granada, 114-18016 Granada, Spain; (I.R.-F.); (J.A.L.)
| | - Jose Antonio Lorente
- GENYO. Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, Liquid Biopsy and Cancer Interception Group, PTS Granada, 114-18016 Granada, Spain; (I.R.-F.); (J.A.L.)
- University of Granada, Legal Medicine and Toxicology Department, Faculty of Medicine, PTS Granada, 18016 Granada, Spain
| | - Fernando Vázquez-Alonso
- Urology Department, Hospital Virgen de las Nieves, 18014 Granada, Spain; (V.S.-C.); (F.V.-A.)
| | - María Jesus Alvarez-Cubero
- GENYO. Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, Liquid Biopsy and Cancer Interception Group, PTS Granada, 114-18016 Granada, Spain; (I.R.-F.); (J.A.L.)
- University of Granada, Department of Biochemistry and Molecular Biology III, Faculty of Medicine, PTS Granada, 18016 Granada, Spain
- Nutrition, Diet and Risk Assessment Group, Bio-Health Research Institute (ibs.GRANADA Instituto de Investigación Biosanitaria), 18014 Granada, Spain
- Correspondence: author: (L.J.M.-G.); (M.J.A.-C.); Tel.: +34-958-715-500 (ext. 108) (L.J.M.-G.); +34-958-248-945 (M.J.A.-C.); Fax: +34-958-637-071 (L.J.M.-G.)
| |
Collapse
|